Skip To Main Content
Lilly
Menu closed
Lilly
  • Account Login / Register
  • Medical Home
    • Medical Information
  • Medical Education
  • Science
Ask Lilly

We're here to help.

Chat
Chat with us Chat with us
Question Contact Us
Expand contact lilly
Lilly

You are now leaving the LillyMedical.com website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to LillyMedical.com.

  1. Medical Information Right
  2. Oncology Right
  3. Jaypirca (pirtobrutinib) tablets Right
  4. What are the efficacy and safety results for the Jaypirca™ (pirtobrutinib) in the phase 1/2 BRUIN trial?
Search Jaypirca (type in keywords)
Search Medical Information

If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)

Loading icon

Jaypirca ™ (pirtobrutinib) tablets

50 mg,100 mg

Full Prescribing Information

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

What are the efficacy and safety results for the Jaypirca™ (pirtobrutinib) in the phase 1/2 BRUIN trial?

In a phase 1/2 BRUIN study, Jaypirca (pirtobrutinib) has shown efficacy in heavily pretreated patients with various B-cell malignancies and the most common TEAEs included fatigue, diarrhea, and neutropenia.

US_cFAQ_PIR001_BRUIN
US_cFAQ_PIR001_BRUIN
en-US

Efficacy Results in Phase 1/2 BRUIN Study

BRUIN is a global, multicenter phase 1/2 trial evaluating pirtobrutinib (LOXO-305) in patients with previously treated chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or non-Hodgkin's lymphoma (NHL) who have failed or are intolerant to standard of care (NCT03740529).1,2 BRUIN Phase 1/2 Study Schema provides additional details on the BRUIN study design.

Mantle Cell Lymphoma

As of the data cut-off date on January 31, 2022, 725 patients had been enrolled in the BRUIN trial, of which 164 were patients with mantle cell lymphoma (MCL). Efficacy analysis was performed in the first 90 patients with MCL who had

  • measurable disease
  • enrolled in either phase 1 or phase 2
  • received a prior Bruton's tyrosine kinase (BTK) inhibitor-containing regimen, and
  • no central nervous system involvement.3

Efficacy Results Among Patients With MCL in the Phase 1/2 BRUIN Study  presents efficacy for patients with MCL in the by prior treatment with a BTK inhibitor as of the data cutoff of January 31, 2022.3 

Efficacy Results Among Patients With MCL in the Phase 1/2 BRUIN Study3 

Response, n (%)

MCL (cBTKi-naïve)a
(n=14)

MCL (Previous cBTKi)b
(n=90)

ORRcd, % (95% CI)

85.7 (57.2-98.2)

57.8 (46.9-68.1)

CR

5 (35.7)

18 (20.0)

PR

7 (50.0)

34 (37.8)

SD

0

14 (15.6)

Median DOR, months (95% CI)

NR

21.6 (7.5-NE)

Median PFS, months (95% CI)

NR

7.4 (5.3-12.5)

Median OS, months (95% CI)

NR

NE (14.8-NE)

Abbreviations: cBTKi = covalent Bruton's tyrosine kinase inhibitor; CR = complete response; DOR = duration of response; IRC = independent review committee; MCL = mantle cell lymphoma; NE = not estimable; NR = not reported; OS = overall survival; PFS = progression-free survival; PR = partial response; SD = stable disease. 

aOne cBTKi naïve patient was not evaluable.

bPrimary analysis set. Nine cBTKi pre-treated MCL patients were not evaluable.

cORR includes patients with a best response of CR and PR.

dResponse status per Lugano 2014 criteria based on IRC assessment.

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

As of the data cut-off date on July 29, 2022, 773 patients had been enrolled in the BRUIN trial, of which 317 were patients with CLL or SLL. Efficacy analysis was performed in 247 patients with CLL/SLL who had

  • enrolled in either phase 1 or phase 2 prior to November 5, 2021
  • received a prior BTK inhibitor-containing regimen, and
  • received one or more doses of pirtobrutinib.4

Efficacy Results Among Patients With CLL/SLL Who Received Prior BTK Inhibitor Treatment in the Primary Analysis Set of the Phase 1/2 BRUIN Study  presents efficacy for patients with CLL/SLL who received prior BTK inhibitor treatment in the efficacy analysis set.4

Efficacy Results Among Patients With CLL/SLL Who Received Prior BTK Inhibitor Treatment in the Primary Analysis Set of the Phase 1/2 BRUIN Study4 

Response, n (%)

CLL/SLL
(n=247)

ORRa, % (95% CI)

82.2 (76.8-86.7)

CR

4 (1.6)

PR

177 (71.7)

PR-L

22 (8.9)

SD

26 (10.5)

Median PFS, months (95% CI)b

19.6 (16.9-22.1)

Abbreviations: BTK = Bruton's tyrosine kinase; CLL = chronic lymphocytic leukemia; CR = complete response; IRC = independent review committee; iwCLL = International Workshop on Chronic Lymphocytic Leukemia; PFS = progression-free survival; PR = partial response; PR-L = partial response with lymphocytosis; SD = stable disease; SLL = small lymphocytic lymphoma. 

aIncludes patients with a best response of CR, PR, and PR-L. Response status per iwCLL 2018 according to IRC assessment.

bMedian follow-up of 19.4 months.

Other Non-Hodgkin's Lymphomas 

In the BRUIN study, patients with other B-cell malignancies, including diffuse large B-cell lymphoma (DLBCL), Waldenström's macroglobulinemia (WM), follicular lymphoma (FL), marginal zone lymphoma (MZL), Richter's transformation (RT), B-cell prolymphocytic leukemia (B-PLL), Hairy Cell Leukemia, primary central nervous system lymphoma (PCNSL), and other transformations, were permitted to enroll.3 Additional efficacy details on these subgroups are included below.

Richter's Transformation

As of the data cut-off date on July 29, 2022, 773 patients had been enrolled in the BRUIN trial, of which 82 were patients with RT. Efficacy analysis was performed in 75 patients with RT who had ≥1 post-baseline response assessment or discontinued treatment prior to first post-baseline response assessment. Of these 75 patients, 68 patients had received prior RT-directed treatment.5

Efficacy Results Among Patients With RT in the Phase 1/2 BRUIN Study  presents efficacy for patients with RT as of the data cutoff of July 29, 2022.5

Efficacy Results Among Patients With RT in the Phase 1/2 BRUIN Study5 

Response, n (%)

All RT Patients
(n=75)

Prior RT Treatment
(n=68)

ORRa, % (95% CI)

52.0 (40.2-63.7)

50.0 (37.6-62.4)

CR

10 (13.3)

9 (13.2)

PR

29 (38.7)

25 (36.8)

SD

10 (13.3)

10 (14.7)

Median DOR, months (95% CI)

5.6 (2.5-NE)

5.4 (1.9-NE)

Median PFS, months (95% CI)

3.7 (2.9-5.1)

3.6 (2.7-4.9)

Median OS, months (95% CI)

13.1 (7.8-NE)

12.8 (7.1-NE)

Abbreviations: CR = complete response; DOR = duration of response; NE = not estimable; OS = overall survival; PFS = progression-free survival; PR = partial response; RT = Richter's transformation; SD = stable disease.

aResponse as assessed by investigator based on Lugano criteria.

Waldenström's Macroglobulinemia

As of the data cut-off date on July 29, 2022, 773 patients had been enrolled in the BRUIN trial, of which 80 were patients with WM. Of these 80 patients, 63 patients had received prior BTK inhibitor treatment.6

Efficacy Results Among Patients With WM in the Phase 1/2 BRUIN Study presents efficacy for patients with RT.6

Efficacy Results Among Patients With WM in the Phase 1/2 BRUIN Study6

Responseab, n (%)

WM (cBTKi-naïve)
(n=17)

WM (Previous cBTKi)
(n=63)

Major response ratec, % (95% CI)

88.2 (63.6-98.5)

66.7 (53.7-78.0)

CR + VGPR, % (95% CI)

29.4 (10.3-56.0)

23.8 (14.0-36.2)

Best response, n (%)

VGPRd

5 (29.4)

15 (23.8)

PR

10 (58.8)

27 (42.9)

MR

0

9 (14.3)

SD

2 (11.8)

9 (14.3)

Median PFS, months (95% CI)

NR

19.4 (15.1-22.1)

Median OS, months (95% CI)

NR

NE

Abbreviations: cBTKi = covalent Bruton's tyrosine kinase inhibitor; CR = complete response; MR = minor response; NE = not estimable; NR= not reported; OS = overall survival; PFS = progression-free survival; PR = partial response; SD = stable disease; VGPR = very good partial response; WM = Waldenström's macroglobulinemia.

aResponse as assessed by investigator based on Modified IWWM6 (Owen’s) criteria.

bTotal % may be different than the sum of the individual components due to rounding.

cMajor response includes subjects with a best response of CR, VGPR, or PR.

dUnder modified IWWM6 criteria, a PR is upgraded to VGPR if corresponding IgM is in normal range or has at least 90% reduction from baseline.

Follicular Lymphoma, Marginal Zone Lymphoma, and Diffuse Large B-Cell Lymphoma

Efficacy Results Among Patients With Other Non-Hodgkin's Lymphomas in the Phase 1/2 BRUIN Study shows efficacy was also demonstrated in other NHLs as of September 27, 2020.

Efficacy Results Among Patientsa With Other Non-Hodgkin's Lymphomas in the Phase 1/2 BRUIN Study7

Responseb

FL
(n=8)

MZL
(n=9)

DLBCL
(n=25)

ORRc, % (95% CI)

50 (16-84)

22 (3-60)

24 (9-45)

CR, n (%)

2 (25)

0

4 (16)

PR, n (%)

2 (25)

2 (22)

2 (8)

SD, n (%)

1 (13)

7 (78)

2 (8)

Abbreviations: CR = complete response; DLBCL = diffuse large B-cell lymphoma; FL = follicular lymphoma; MZL = marginal zone lymphoma; ORR = overall response rate; PR = partial response; SD = stable disease.

aEfficacy evaluable patients are those who had at least one postbaseline response assessment or had discontinued treatment prior to first postbaseline response assessment.

bTotal percentage may be different than the sum of the individual components due to rounding.

cResponses were defined according to disease-specific guidelines. As of data cutoff, no responses were observed in the efficacy evaluable patients with other tumor types not shown in the table. ORR includes patients with a best response of CR and PR. Response status per Lugano criteria.

Safety Results in Phase 1/2 BRUIN Study

The median time on treatment for the overall safety population was 9.6 months. Treatment-related adverse events led to 

  • treatment discontinuations in 2.6% (n=20) of all patients, and
  • dose reductions in 4.5% (n=35) of all patients.5

Adverse events that occurred in ≥15% of patients in the overall BRUIN study are summarized in Adverse Events Occurring in ≥15% of the Overall Study Population of the Phase 1/2 BRUIN Study . Adverse events of special interest in the overall BRUIN study are summarized in Adverse Events of Special Interest Among Patients in the Overall Study Population of the the Phase 1/2 BRUIN Study.

Adverse Events Occurring in ≥15% of the Overall Study Population of the Phase 1/2 BRUIN Study5 

Adverse Event, % of patients

All Doses and Patients
(N=773)

TEAEs

TRAEs

Any Grade

Grade ≥3

Any Grade

Grade ≥3

Fatigue

28.7

2.1

9.3

0.8

Diarrhea

24.2

0.9

9.3

0.4

Neutropeniaa

24.2

20.4

14.7

11.5

Contusion

19.4

0

12.8

0

Cough

17.5

0.1

2.3

0

Covid-19

16.7

2.7

1.3

0

Nausea

16.2

0.1

4.7

0.1

Dyspnea

15.5

1.0

3.0

0.1

Anemia

15.4

8.8

5.2

2.1

Abbreviations: TEAE = treatment-emergent adverse event; TRAE = treatment-related adverse event.

aAggregate of neutropenia and neutrophil count decreased.

Adverse Events of Special Interest Among Patients in the Overall Study Population of the the Phase 1/2 BRUIN Study5

Adverse Event of Special Interesta, % of patients

All Doses and Patients
(N=773)

TEAEs

TRAEs

Any Grade

Grade ≥3

Any Grade

Grade ≥3

Bruisingb

23.7

0

15.1

0

Rashc

12.7

0.5

6.0

0.4

Arthralgia

14.4

0.6

3.5

0

Hemorrhage/hematomad

11.4

1.8

4.0

0.6

Hypertension

9.2

2.3

3.4

0.6

Atrial fibrillation/fluttere

2.8f

1.2

0.8

0.1

Abbreviations: BTK = Bruton's tyrosine kinase; TEAE = treatment-emergent adverse event; TRAE = treatment-related adverse event.

aAdverse events of special interest are those that were previously associated with covalent BTK inhibitors.

bAggregate of contusion, petechiae, ecchymosis, and increased tendency to bruise.

cAggregate of all preferred terms including rash.

dAggregate of all preferred terms including hematoma or hemorrhage.

eAggregate of atrial fibrillation and atrial flutter.

fOf the 22 total atrial fibrillation/atrial flutter TEAEs in the overall safety population, 7 occurred in patients with a prior medical history of atrial fibrillation.

Patient Characteristics in Phase 1/2 BRUIN Study 

Baseline patient characteristics and treatment history among patients with MCL, CLL/SLL, RT, and WM in the BRUIN study are summarized in Baseline Characteristics Among Patients with MCL, CLL/SLL, RT, and WM in the Phase 1/2 BRUIN Study and Treatment History Among Patients with MCL, CLL/SLL, RT, and WM in the Phase 1/2 BRUIN Study , respectively.

Baseline Characteristics Among Patients with MCL, CLL/SLL, RT, and WM in the Phase 1/2 BRUIN Study

Characteristic

MCL (prior BTKi)a3
(n=90)

CLL/SLLb4
(n=247)

RTb5
(n=82)

WM (prior BTKi)b6
(n=63)

Median age, years (range)

70 (46-87)

69 (36-88)

67 (26-95)

69 (42-84)

Male, n (%)

72 (80)

168 (68)

55 (67)

42 (67)

ECOG PS, n (%)

0

61 (68)

133 (54)

32 (39)

34 (54)

1

28 (31)

97 (39)

38 (46)

28 (44)

2

1 (1)

17 (7)

12 (15)

1 (2)

Median lines of prior systemic therapy, (range)

3 (1-11)

3 (1-11)

2 (0-13)

3 (1-11)

Reason discontinued any prior BTKicd, n (%)

Progressive disease

74 (82)

190 (77)

NR

41 (65)

Toxicity/other

16 (18)

57 (23)

NR

21 (33)

Abbreviations: BTKi = Bruton's tyrosine kindase inhibitor; CLL = chronic lymphocytic leukemia; ECOG = Eastern Cooperative Oncology Group; MCL = mantle cell lymphoma; PS = performance status; RT = Richter's transformation; SLL = small lymphocytic lymphoma; WM = Waldenström's macroglobulinemia. 

aData cutoff of January 31, 2022.

bData cutoff of July 29, 2022.

cIn the event more than one reason was noted for discontinuation, disease progression took priority.

dOne patient with WM had unknown reason for prior BTK inhibitor discontinuation.

Treatment History Among Patients with MCL, CLL/SLL, RT, and WM in the Phase 1/2 BRUIN Study 

Prior Therapy, n (%)

MCL (prior BTKi)a3
(n=90)

CLL/SLLb4
(n=247)

RTb5
(n=82)

WM (prior BTKi)b6
(n=63)

BTK inhibitor

90 (100)

247 (100)

28 (34)

63 (100)

Anti-CD20 antibody

86 (96)

217 (88)

64 (78)

58 (92)

Chemotherapy

79 (88)

195 (79)

62 (76)

52 (83)

BCL2 inhibitor 

14 (16)

100 (41)

31 (38)

4 (6)

PI3K inhibitor

3 (3)

45 (18)

8 (10)

3 (5)

CAR-T

4 (4)

14 (6)

9 (11)

NR

Stem cell transplant

19 (21)

6 (2)

5 (6)

4 (6)

Immunomodulator

19 (21)

NR

3 (4)

6 (10)

Abbreviations: BCL2 = B-cell lymphoma-2; BTK = Bruton's tyrosine kinase; CAR-T = chimeric antigen receptor T cells; CLL = chronic lymphocytic leukemia; MCL = mantle cell lymphoma; NR = not reported; PI3K = phosphatidylinositol-3-kinase; RT = Richter’s transformation; SLL = small lymphocytic lymphoma; WM = Waldenström's macroglobulinemia.

aData cutoff of January 31, 2022.

bData cutoff of July 29, 2022.

BRUIN Phase 1/2 Clinical Study

The primary endpoints of the phase 1 portion of the BRUIN study are maximum tolerated dose and recommended phase 2 dose. The primary endpoint of the phase 2 portion of the study is overall response rate by independent review committee. Key secondary endpoints of the phase 2 portion of the study are 

  • duration of response
  • overall survival
  • progression free survival
  • safety and tolerability, and
  • pharmacokinetics.1,2

BRUIN Phase 1/2 Study Schema describes the design of the BRUIN study.

BRUIN Phase 1/2 Study Schema1